The company has mastered the "process platform technology for large-scale vaccine preparation in bioreactors" through "introduction, digestion, absorption, and re-innovation", and has overcome the problem of large-scale animal cell culture preparation of high-quality vaccines in my country for more than ten years. technical difficulties. The "Chengda Suda" human rabies vaccine produced using this technology has broken the long-term monopoly of multinational companies on high-end human rabies vaccines in my country. All technical indicators have reached the advanced level of similar international products and has become China's human rabies vaccine. The first brand, it has been exported to more than ten countries including India, and is in the process of product registration in Vietnam and other countries.
After Chengda Suda was launched, a large number of phase 4 clinical observations were conducted at home and abroad, and a wealth of clinical research data was accumulated. At present, Chengda Suda human rabies vaccine has vaccinated nearly 20 million people, and so far no complete discovery has been made. In cases of immune failure, the vaccine has become the preferred vaccine for rabies prevention and control in China. The swine fever vaccine produced by high-density culture of mini pig kidney cells (MPK cells) imported from abroad in advanced bioreactors is currently in the technical docking stage. This product is produced and used in Italy and other countries and is a low-cost, high-quality product.
As subsequent products will be put on the market one after another, with leading technical indicators and product quality, it is expected to become a new profit growth point for the company.